Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs to have its price slashed in bargaining with the US government, a company executive said.
“It is very likely that Ozempic will be part of negotiations in the coming round, and we’re ready for that,” Ulrich Otte, senior vice president of finance & operations for Novo Nordisk, said Tuesday at Cantor Global Healthcare Conference in New York.
The US Centers for Medicare and Medicaid Services will announce the next set of 15 retail prescription drugs selected for negotiation by February 1, 2025, according to KFF. CMS will announce maximum fair prices for these drugs by November 30, 2025, with negotiated prices available on January 1, 2027.
Obesity is an epidemic that has massive ripples throughout healthcare driving up costs. Whether or not you think people should “put down the fork” or not doesn’t matter. People losing weight is good for individuals and society. And if Ozempic is what does it, great. As long as it gets done.
Ozempic’s time is numbered anyhow. It only has like 7 more years on patent before it can be offered generic. And there are more and better GLP-1s (tirzepitide, retatrutide, etc) on or coming on the market very soon, so competition should drive down prices.
3 comments
Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs to have its price slashed in bargaining with the US government, a company executive said.
“It is very likely that Ozempic will be part of negotiations in the coming round, and we’re ready for that,” Ulrich Otte, senior vice president of finance & operations for Novo Nordisk, said Tuesday at Cantor Global Healthcare Conference in New York.
The US Centers for Medicare and Medicaid Services will announce the next set of 15 retail prescription drugs selected for negotiation by February 1, 2025, according to KFF. CMS will announce maximum fair prices for these drugs by November 30, 2025, with negotiated prices available on January 1, 2027.
Obesity is an epidemic that has massive ripples throughout healthcare driving up costs. Whether or not you think people should “put down the fork” or not doesn’t matter. People losing weight is good for individuals and society. And if Ozempic is what does it, great. As long as it gets done.
Ozempic’s time is numbered anyhow. It only has like 7 more years on patent before it can be offered generic. And there are more and better GLP-1s (tirzepitide, retatrutide, etc) on or coming on the market very soon, so competition should drive down prices.